Comments on: Adding Investigational Agent Elotuzumab to Standard Treatment for Multiple Myeloma Significantly Reduced the Risk of Disease Progression, According to New Phase III Data from ELOQUENT-2 Trial Published in New England Journal of Medicine

Comments on: Adding Investigational Agent Elotuzumab to Standard Treatment for Multiple Myeloma Significantly Reduced the Risk of Disease Progression, According to New Phase III Data from ELOQUENT-2 Trial Published in New England Journal of Medicine https://www.worldpharmatoday.com/press-releases/adding-investigational-agent-elotuzumab-to-standard-treatment-for-multiple-myeloma-significantly-reduced-the-risk-of-disease-progression-according-to-new-phase-iii-data-from-eloquent-2-trial-published/ Magazine for the C-level Pharma Executives Mon, 01 Jun 2015 18:30:00 +0000 hourly 1 https://wordpress.org/?v=6.9.4